CYP2C19 genotype and early ischemic lesion recurrence in stroke patients treated with clopidogrel

Tae Dong Jeong, Seung Min Kim, Hyo Jin Kim, Woochang Lee, Sun U. Kwon, Won Ki Min, Dong Wha Kang, Sail Chun

Research output: Contribution to journalArticlepeer-review

21 Scopus citations


Background Early recurrent ischemic lesions detected on diffusion-weighted imaging (DWI) have been proposed as a surrogate marker for clinical recurrence. We hypothesized that cytochrome P450 2C19 (CYP2C19) genotype influences the incidence of early recurrence on DWI in acute stroke patients treated with clopidogrel. Methods We enrolled 76 Korean patients with acute ischemic stroke due to large artery atherosclerosis who were treated with clopidogrel. Early ischemic lesion recurrence was defined as new lesions separate from the index lesion. We compared the rates of early ischemic lesion recurrence on DWI based on the CYP2C19 genotypes. Results Early recurrence on DWI was observed in 36 patients (47.4%). A total of 76 patients were classified into 3 phenotypic groups: extensive metabolizers (EMs; n = 27, 35.5%), intermediate metabolizers (IMs; n = 36, 47.4%), and poor metabolizers (PMs; n = 13, 17.1%). Early recurrence on DWI was more common in PMs (84.6%), followed by IMs (50.0%), and EMs (25.9%; P <.001). PMs had a significantly higher recurrence rate than EMs (P <.001). In multivariate analysis, CYP2C19 genotypes were independently associated with early DWI recurrence (for PMs: odds ratio, 19.3; 95% confidence interval, 3.15-117.56). Conclusions CYP2C19 genotypes are significantly associated with early lesion recurrence in Korean acute stroke patients treated with clopidogrel.

Original languageEnglish
Pages (from-to)440-446
Number of pages7
JournalJournal of Stroke and Cerebrovascular Diseases
Issue number2
StatePublished - 1 Feb 2015

Bibliographical note

Funding Information:
This study was supported by the grant from the Korea Health Technology R&D Project, Ministry of Health and Welfare , Republic of Korea ( HI12C1847 ).

Publisher Copyright:
© 2015 National Stroke Association.


  • Clopidogrel
  • CYP2C19
  • diffusion magnetic resonance imaging
  • genotype
  • recurrence
  • stroke


Dive into the research topics of 'CYP2C19 genotype and early ischemic lesion recurrence in stroke patients treated with clopidogrel'. Together they form a unique fingerprint.

Cite this